Researchsurvodutideboehringer ingelheimdiabetic kidney diseaseglucagon receptor

Survodutide cuts albuminuria and glomerulosclerosis in mouse model of diabetic kidney disease

The dual glucagon/GLP-1 receptor agonist was given at 7.5 nmol/kg daily for 10 weeks in uninephrectomized renin-overexpressing db/db mice.

By Priya Raman · Science Reporter

Sep 30 20:00 ETSource: Diabetes, obesity & metabolism

The wire

01In Diabetes, Obesity & Metabolism, daily subcutaneous survodutide at 7.5 nmol/kg for 10 weeks reduced body weight, hyperglycemia and HbA1c while improving albuminuria, glomerulosclerosis, kidney hypertrophy and inflammation versus vehicle.
02Survodutide is in phase 3 for obesity and MASH; renal findings suggest a possible additional indication clinicians following incretin pipelines may see tested.
03This is a mouse model of advanced diabetic kidney disease using adeno-associated virus renin overexpression and uninephrectomy; the authors call only for further investigation in chronic kidney disease.

From the source

Nephroprotective Effects of the Dual GCGR/GLP-1R Agonist Survodutide in Hypertension-Accelerated Diabetic Kidney Disease
Diabetes, obesity & metabolism · 2026 Oct 1 · Hamilton A, Thisted L, Ougaard M et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42823075/